Global /China /Healthcare /Drug Manufacturers - General /002393

Tianjin Lisheng Pharmaceutical Co.,Ltd.

002393

• SHE: 002393 • Delayed

16.70CNY -0.7%

2.47 USD

As of 21 June 2026, Tianjin Lisheng Pharmaceutical Co.,Ltd. has a market cap of $766.49M USD, ranking #12350 globally and #3685 in China. It ranks #1129 in the Healthcare sector, and #420 in the Drug Manufacturers - General industry.

Global Rank

12350

Country Rank

3685

Sector Rank

1129

Industry Rank

420

Key Stats

Market Cap

$766.49MUSD

5.18B CNY

Enterprise Value

$409.92MUSD

2.77B CNY

Revenue (TTM)

$200.44MUSD

1.35B CNY

EBITDA (TTM)

$26.78MUSD

181.28M CNY

Net Income (TTM)

$61.1MUSD

412.89M CNY

EBITDA Margin

13%

Profit Margin

30%

PE Ratio

12.5

PS Ratio

3.8

PB Ratio

1.1

EV/EBITDA

15.0

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Fujun Wang open_in_new

Employees

1,605

Founded

1951

Website

lishengpharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-0.7%	-12%	-15%	-9.2%	-7.6%	-7.1%	22%	18%	47%

News

Markets

Exchange	Ticker	Price	Quotes
Shenzhen Stock Exchange (SHE / SZSE) MIC: XSHE PRIMARY	002393 天津力生制药股份有限公司 Class A ISIN: CNE100000NJ9 Shares Out.: Shares Outstanding: 302.301M¹ Shares Float: 137.151M² TV: TradingView: SZSE: 002393 SA: Stock Analysis: SHE: 002393 YF: Yahoo Finance: 002393.SZ GF: Google Finance: SHE: 002393 BA: Barron's: 002393 MS: Morningstar: XSHE: 002393	16.70 CNY	TV: TradingView: SZSE: 002393 SA: Stock Analysis: SHE: 002393 YF: Yahoo Finance: 002393.SZ GF: Google Finance: SHE: 002393 BA: Barron's: 002393 MS: Morningstar: XSHE: 002393

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Tianjin Lisheng Pharmaceutical Co.,Ltd.

Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers pharmaceutical, traditional Chinese medicine, and antibiotic products in various forms, such as oral solid dosage forms, soft capsules, sterile preparations, and raw materials primarily for cardiovascular and digestive system applications. Its products also include Shoubishan capsules, Jiayindapamide tablets, Sanyu Zhengtong tablets, Xifuni cefdinir dispersible tablets, and Youhao Maren soft capsules. In addition, the company provides pharmaceutical manufacturing outsourcing services and technology research and development services. Further, it exports its products. The company was founded in 1951 and is headquartered in Tianjin, China. Tianjin Lisheng Pharmaceutical Co.,Ltd. operates as a subsidiary of Tianjin Jinhao Pharmaceutical Co., Ltd.

Similar Companies

Industry: Drug Manufacturers - General (China)

Name	Market Cap (USD) diff.	PE	Country
Jiangsu Hengrui Pharmaceuticals Co.,Ltd SSE: 600276	$54.0B 364.89B CNY 7K%	44.9	China
WuXi AppTec Co., Ltd. SSE: 603259	$49.78B 336.36B CNY 6K%	17.2	China
Hansoh Pharmaceutical Group Company Ltd. SHEK: 3692	$28.51B 223.48B HKD 4K%	35.7	China
Innovent Biologics, Inc. SHEK: 1801	$18.8B 147.32B HKD 2K%	162.3	China
Sichuan Biokin Pharmaceutical Co.,Ltd. SSE: 688506	$16.56B 111.89B CNY 2K%	-	China
Akeso, Inc. SHEK: 9926	$16.01B 125.46B HKD 2K%	-	China

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 99K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 71K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 47K%	97.4	United States
Roche Holding AG SIX: RO	$318.3B 256.25B CHF 41K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$284.64B 215.59B GBP 37K%	27.6	United Kingdom
Merck & Co., Inc. NYSE: MRK	$274.03B 36K%	15.1	United States

chevron_leftBack